Press Releases 2012

PsychoGenics Achieves Substantial Milestone in its Drug Discovery Collaboration with Sunovion

November 5, 2012 – Tarrytown, New York. - PsychoGenics today announced that the Food and Drug Administration (FDA) has accepted Sunovion’s IND for SEP360, triggering a milestone payment to PsychoGenics, and that human dosing has been initiated. Read More.

Afraxis and PsychoGenics Form Alliance to Offer Afraxis’ ESP Technology for Drug Discovery

July 16, 2012 – San Diego and Tarrytown, New York. - Afraxis and PsychoGenics today announced an alliance to offer Afraxis’ Enhanced Spine Platform (ESP) technology as part of PsychoGenics’ comprehensive testing capabilities and drug discovery services. Read More.

PsychoGenics Inc. Announces Positive Efficacy Data in Levodopa Induced Dyskinesia in Parkinson’s Patients.

June 12, 2012 – Tarrytown, New York. - PsychoGenics Inc. today reported positive results from a clinical study of eltoprazine in levodopa induced dyskinesia (LID) in Parkinson's disease (PD) patients. Eltoprazine met the primary objective of the study by exhibiting a statistically significant reduction in LID at the 5 mg dose (p = 0.0007) and the 7.5 mg dose (p = 0.0467), without adversely affecting levodopa efficacy. Eltoprazine was also well tolerated in this study and there were no serious adverse events. Read More.

PsychoGenics Expands its In Vivo Capabilities with the Addition of Preclinical Magnetic Resonance Imaging Technology Services in Partnership with Ekam Imaging.

February 08, 2012 – Tarrytown, New York. and Boston, MA., PsychoGenics Inc. and Ekam Imaging, Inc., today announced the establishment of an alliance to provide Ekam’s specialized imaging services in awake animals to complement PsychoGenics’ testing capabilities and drug discovery services. Read More.


  • PsychoGenics
  • 215 College Road, Paramus, NJ 07652
  • Tel: (914) 406-8000
  • Fax: (914) 406-8090